SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 6, 2001
COR THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-19290 94-3060271
(State of jurisdiction) (Commission File No.) (IRS Employer Identification No.)
256 East Grand Avenue
South San Francisco, California 94080
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (650) 244-6800
1.
Item 5. Other Events
On June 6, 2001, COR Therapeutics, Inc., a Delaware corporation, announced that
it has entered into an agreement for the sale of $250 million of convertible
senior notes ($300 million if the over-allotment option is exercised in full)
through a Rule 144A offering to qualified institutional buyers.
A copy of COR's press release announcing the private placement is attached
hereto as Exhibit 99.1.
Item 7. Exhibits
Exhibit 99.1 Press Release, dated June 6, 2001.
2.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
COR THERAPEUTICS, INC.
Dated: June 6, 2001 By: /s/ Patrick Broderick
------------ ---------------------------------------
Patrick Broderick
Senior Vice President and General Counsel
3.